Virtu Financial’s Seres Therapeutics MCRB Stock Holding History

Virtu Financial’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,940	Closed	-$56K	–	1844
2024 Q3	$56K	Buy	2,940 +910	+45%	+$18.5K	﹤0.01%	995
2024 Q2	$29K	Sell	2,030 -2,696	-57%	-$45K	﹤0.01%	985
2024 Q1	$73K	Buy	+4,726	New	+$102K	0.01%	968
2022 Q1	–	Sell	-1,721	Closed	-$287K	–	1805
2021 Q4	$287K	Buy	+1,721	New	+$273K	0.03%	649
2021 Q2	–	Sell	-1,167	Closed	-$481K	–	1840
2021 Q1	$481K	Buy	+1,167	New	+$537K	0.03%	536
2019 Q4	$39K	Buy	+560	New	+$41.5K	﹤0.01%	1243
2019 Q3	–	Sell	-736	Closed	-$47K	–	1660
2019 Q2	$47K	Buy	+736	New	+$69.9K	﹤0.01%	1250
2018 Q2	–	Sell	-533	Closed	-$78K	–	2295
2018 Q1	$78K	Buy	+533	New	+$102K	﹤0.01%	1626
2017 Q4	–	Sell	-774	Closed	-$248K	–	2738
2017 Q3	$248K	Buy	+774	New	+$212K	0.01%	1582

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial's MCRB Position: Q4 2024 in Review

Virtu Financial sold out of Seres Therapeutics (MCRB) in Q4 2024, closing a stake of 2,940 shares — an estimated $56K sold.

Virtu Financial first reported a position in MCRB in Q3 2017 and held it in 9 quarters. The position peaked at $481K in Q1 2021. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2024.

Virtu Financial reported no remaining Seres Therapeutics position as of Q4 2024 after selling out during the quarter.
Virtu Financial sold 2,940 Seres Therapeutics shares in Q4 2024, an estimated $56K.
Virtu Financial first reported a position in Seres Therapeutics in Q3 2017 and held it in 9 quarters.
Virtu Financial's Seres Therapeutics position peaked at $481K in Q1 2021.
69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2024.

Based on Virtu Financial's 13F filing for Q4 2024, filed 11 Feb 2025.